IKS Health to buy TruBridge at $26.25 per share in 2026

Deal announcement and why it matters

Inventurus Knowledge Solutions, Inc. (IKS), the US subsidiary of Inventurus Knowledge Solutions Limited (NSE: IKS; BSE: 544309), said it has entered into a definitive agreement to acquire TruBridge, Inc. (NASDAQ: TBRG). TruBridge is positioned as a healthcare technology provider focused on rural and community hospitals in the United States. The companies framed the transaction as a move to broaden access to care by strengthening the tools used by clinicians and hospitals in underserved regions. For IKS Health, the acquisition also marks a bigger push into electronic health records (EHR) and revenue cycle management (RCM) for smaller US hospitals.

The announcement is notable for Indian-market investors because Inventurus Knowledge Solutions Limited is listed in India, while the target is listed in the US. The disclosed deal structure, financing plan, and regulatory timeline provide a clearer roadmap than earlier reports that described the talks as preliminary.

Who is acquiring whom

IKS, described as the US subsidiary of Inventurus Knowledge Solutions Limited (also referred to as IKS Health), will acquire TruBridge. The transaction is being pursued through the group’s US arm, keeping the operating integration centered in the US market where TruBridge’s customers are based. TruBridge is described as a provider of healthcare technology solutions for rural and community hospitals, with offerings including EHR, RCM, and data management services.

The companies said the combined organisation is expected to support more than 2,000 healthcare organisations and over 150,000 clinicians. TruBridge itself serves over 700 community and critical-access hospitals across the US, according to the disclosures cited in the provided text.

Transaction structure and consideration

Under the terms disclosed, TruBridge shareholders will receive $16.25 in cash per share of common stock. The reporting included two valuation references: a total consideration of up to $165 million, and an enterprise value of about $157 million for TruBridge.

The deal has been approved by the Boards of Directors of IKS Health, IKS, and TruBridge. The closing is expected during the third calendar quarter of 2026, subject to customary conditions. These include shareholder approvals and the Hart-Scott-Rodino (HSR) notification and waiting period.

Financing plan and lenders involved

IKS said it will finance the acquisition primarily through new indebtedness. The disclosures referenced a term loan underwritten by Citibank, JPMorganChase, and Deutsche Bank, subject to customary conditions, including approval of IKS Health shareholders.

A separate financing breakdown in the provided material stated IKS Inc. has secured committed financing of up to $170 million, including:

• a $110 million term loan,
• a $10 million secondary term loan, and
• a $10 million revolving credit facility.

Initial leverage is expected to be around three times EBITDA of the combined entity, according to the same source text.

What the combined platform plans to offer

The companies said the combined organisation will bring modern revenue cycle management, predictive analytics, and advanced EHR capabilities. The stated intent is to deliver a broader portfolio of AI-driven and human-led solutions designed to improve clinical, operational, and financial performance. The description also referenced integrating agentic artificial intelligence with human expertise to address operational challenges and build connected workflows.

Separately, the deal rationale in the provided material highlighted a plan to combine TruBridge’s EHR “system of record” with IKS Health’s care-enablement capabilities, positioning the platform across both ambulatory and acute care settings.

TruBridge snapshot: customers and financial reference points

TruBridge operates in the Healthcare Providers and Services industry and was described as having a market capitalisation of approximately $141.07 million in one part of the provided text. Another portion referred to a market cap “about $100 million” after a reported share move.

TruBridge reported revenue of $147 million in calendar year 2025, as cited in the provided material. The same material stated TruBridge’s adjusted EBITDA margin was about 20%.

Approvals, filings, and regulatory checkpoints

The transaction is subject to customary closing conditions, including required shareholder approvals and the HSR notification and waiting period in the US. TruBridge is expected to file a Current Report on Form 8-K with the US Securities and Exchange Commission (SEC) in connection with the acquisition.

The provided text also stated TruBridge’s largest shareholders, representing approximately 27% of outstanding shares, have agreed to vote in favour of the transaction.

Market reaction and listed-market context

The announcement was described as being made after market hours. On the day referenced, shares of IKS Health rose 0.55% on the BSE to close at Rs. 1,435.40, while the benchmark Sensex fell 1.09% to 77,664.

Separately, the compilation of reports referenced TruBridge shares rising 13% following acquisition news, though the same section also described the acquisition discussions as “talks” in an earlier phase.

Earlier media reports and the April 14 clarification

The provided material included an earlier clarification from Inventurus Knowledge Solutions Limited to BSE dated April 14, 2026, in response to a report describing a potential acquisition. The company said its subsidiary had participated in discussions, but that no binding agreements had been executed at that time, and that discussions were non-binding and subject to contingencies.

The April 23, 2026 disclosure of a “definitive agreement” materially changes that status, shifting the deal from exploratory discussions to a signed transaction subject to approvals and closing conditions.

Key deal facts at a glance

What investors may track next

The near-term watchpoints are procedural and financing-related: shareholder approvals (including IKS Health shareholder approval tied to financing conditions), the HSR process in the US, and the specific terms of the debt package at closing. Investors will also track TruBridge’s SEC filings, including the referenced Form 8-K, for additional transaction details.

From an operating standpoint, the stated focus is on expanding EHR and RCM capabilities for rural and community hospitals, while adding predictive analytics and broader clinical-financial data workflows. The timeline disclosed places the next major milestone in Q3 2026, when the companies expect to complete the transaction subject to all conditions being met.